anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a drink containing the components of cistanche deserticola and coffee, in particular to the cistanche deserticola coffee consisting of cistanche genus plants, coffee and other additives which can be in a solid state or in a liquid state. In one specific proposal of the invention, the cistanche genus plants can be any one or combination of a plurality of the extract, crude drugs, decoction pieces, whole powder, ultrafine powder or solution of cistanche tubulosa, cistanche and cistanche salsa; the extract of the cistanche tubulosa of the cistanche genus plants is preferred. In another specific proposal, the coffee is any one or the combination of a plurality of coffee beans, whole coffee powder, ultrafine coffee powder or soluble coffee in a solid or liquid state; the soluble coffee is much more preferred. The drink organically combines the features of the cistanche genus plants and coffee, and is easy to drink. If drunk for a long time, the drink has the effect of anti-fatigue, nourishing and strengthening muscles, enhancing immunity, reducing blood lipid, gaining sunny color and anti-aging, etc. If the cistanche genus plants are the cistanche tubulosa from Hetian, the effect of the drink is much better.
PURPOSE:To beautifully remove hair in a short time without unpleasant smell and acute pain, by applying a hair removing agent prepared by adding a depilation chemical and a low-thixotropy imparting ingredient to a solution of a film-forming high polymer to a part for removing hair, drying the resultant coat and peeling the formed film. CONSTITUTION:A depilation chemical and ingredient for imparting low thixotropy are added to an aqueous solution of a high polymer, e.g. PVA, PVP, etc., or emulsion, e.g. polyacrylic acid ester, etc., having film-forming properties to give a hair removing agent. Short fibers having 1-10mm length and 1-10mum thickness are preferred for the ingredient to impart low thixotropy and the amount thereof to be added is 2-10wt%. Since the agent has low thixotropy, it has improved extensibility and can be uniformly applied. Furthermore, the agent has the following characteristic. Since the film formation is accelerated and the film is reinforced, no residual material is left in the part for removing the hair.
Cardiovascular disease is a prevalent complication in patients with end-stage renal disease (ESRD) on maintenance hemodialysis. In the ESRD patient population, cardiovascular mortality is 20 times higher compared to the general population. The strong relationship between both illnesses can be explained through cardiorenal syndrome (CRS). CRS encompasses a spectrum of disorders involving both the heart and kidneys in which acute or chronic dysfunction in one organ may induce a similar effect in the other organ. Current literature reveals that inflammation and thrombosis are integral to CRS development. Hence, this study aims to demonstrate whether thromboinflammatory biomarkers and laboratory parameters correlate with ESRD progression and the development of CRS. Ninety-five ESRD patients were recruited at Loyola University Medical Center hemodialysis unit. Epic chart analysis was used to determine patients with CRS. Biomarkers (C-reactive protein, tumor necrosis factor alpha, interleukin-6, Annexin V, L-fatty acid binding protein, monocyte chemoattractant protein 1, nitric oxide, von Willebrand factor, D-dimer, and plasminogen activator inhibitor-1) were profiled using the enzyme-linked immunosorbent assay method in patients with and without CRS in the ESRD cohort. All biomarkers were significantly elevated in ESRD patients compared to normal controls (P < .05) and laboratory parameters, ferritin (521.99 ± 289.33) and PTH (442.91 ± 1.50). Through EPIC chart analysis 47% of ESRD patients have CRS. D-dimer and TNF-α were significantly elevated in patients with CRS compared to patients without CRS. This study suggests that biomarkers, D-dimer, and TNF-α, can be good predictors of CRS in ESRD patients.
PURPOSE:To obtain an agent capable of suppressing the formation of tyrosinase beforehand in place of inhibiting the action and activity of the enzyme, and useful in the fields of pharmaceuticals, cosmetics, etc., by using propionic acids, butyric acids and valeric acids as active components. CONSTITUTION:The objective agent can be produced by using an active component comprising one or more compounds selected from propionic acids, butyric acids and valeric acids which are tyrosinase-formation inhibiting substances having high safety and stability and forming the active component in the form of a drug by conventional method. The concentration of the tyrosinase-formation inhibiting substance is usually 0.001-1.0M and the pH of the agent is adjusted to 2.5-9.0. The daily dose of the tyrosinase-formation inhibiting substance is 0.001-100g for adult. The tyrosinase-formation inhibiting agent has strong effect to suppress the formation of melanin and gives fair skin. It can be formed in the form of injection, oral drug, external medicine, bathing agent, milky lotion, pack, cream and the like.
The invention relates to radiopharmaceuticals which preferentially accumulate in myocardial tissue. The invention particularly relates to a radiopharmaceutical composition which contains as effective radioactive compound a Tc(III)-DMPE complex with a chloride ion and a hydroxyl group as coligands. A process for preparing this composition entails technetate(VII) being reacted with the reducing ligand DMPE in one step to give the desired complex by, to prepare the inactive precursor (instant kit), together with the DMPE . HCl from aqueous alcoholic solution, additives of mannitol and either a dicarboxylic acid, an aminopolycarboxylic acid or a polyaminocarboxylic acid being lyophilised, and a 1/1 mixture of pertechnetate generator eluate and propylene glycol being added to this lyophilised mixture, and the mixture being heated until conversion to (Tc(DMPE)2Cl(OH))<+> is complete. After neutralisation with NaHCO3 solution, the solution is ready for injection. This composition permits images of the myocardium which can be satisfactorily evaluated to be obtained up to 4 hours after the injection.
There is a regional preference around lymph nodes (LNs) for adipose beiging. Here, we show that local LN removal within inguinal white adipose tissue (iWAT) greatly impairs cold-induced beiging, and this impairment can be restored by injecting M2 macrophages or macrophage-derived C-C motif chemokine (CCL22) into iWAT. CCL22 injection into iWAT effectively promotes iWAT beiging, while blocking CCL22 with antibodies can prevent it. Mechanistically, the CCL22 receptor, C-C motif chemokine receptor 4 (CCR4), within eosinophils and its downstream focal adhesion kinase/p65/interleukin-4 signaling are essential for CCL22-mediated beige adipocyte formation. Moreover, CCL22 levels are inversely correlated with body weight and fat mass in mice and humans. Acute elevation of CCL22 levels effectively prevents diet-induced body weight and fat gain by enhancing adipose beiging. Together, our data identify the CCL22-CCR4 axis as an essential mediator for LN-controlled adaptive thermogenesis and highlight its potential to combat obesity and its associated complications.
Muslims constitute approximately 20% of the world's population. In South Africa, Muslims constitute just under 2% of the total population. Fasting is one of the mandatory activities of adherents of the Islamic faith, where all healthy adult Muslims abstain from food, drink, and sexual activities between dawn and dusk during the month of Ramadhan. Medical doctors are frequently required to provide advice to their Muslim patients about the safety or other health impacts of this type of fasting. This narrative review provides an overview of research conducted on Muslim populations during the fasting period, with special reference to non-communicable diseases (NCDs) that are prevalent in the Muslim community. In the absence of evidence-based clinical guidelines, this article summarises the latest published research on this topic, providing a resource for clinicians and researchers. This paper provides an evidence summary to clinicians when engaging with their patients who may be engaging in Ramadhan fasting, while also identifying gaps in the body of evidence that could inform future research.
Patients undergo standard of care ASCT with a conditioning regimen of melphalan. Beginning 60-120 days after ASCT, patients receive daratumumab IV every week for 8 weeks, every 2 weeks for 16 weeks, and then every 4 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
Considering the widespread issue of distracted eating, our study investigates how cognitive distraction influences the sensory perception of food-related odors among individuals with varying weight statuses. We conducted an exploratory, randomized, and cross-sectional experimental study, using the Tetris game to simulate real-life cognitive distraction, incorporating two distraction levels (low and high) and presenting five distinct odors. A total of 59 participants, categorized into a lean (n = 30) and overweight/obese group (n = 29) based on their body mass index (BMI), received odor stimuli while playing Tetris at low and high difficulty, corresponding to low and high distraction levels, respectively. Participants subsequently rated odor intensity and pleasantness under the two cognitive distraction conditions. Respiratory movements were monitored to ensure accurate olfactory stimulation. Our findings revealed no significant difference in odor intensity ratings across distraction levels (p = 0.903). However, there was a significant reduction in odor pleasantness under high cognitive distraction (p = 0.007), more pronounced in lean participants compared to those with an overweight status (p = 0.035). Additionally, an interaction between gender and cognitive distraction effects was observed in odor pleasantness perception. The differential effects of distraction across weight-status groups and genders are discussed in the context of hedonic motivation and compensatory mechanisms. This study sheds light onto the sensory mechanisms underlying distracted eating and could inform more personalized strategies for promoting healthier eating habits in a world dominated by distractions.
The invention relates to the technical field of preparation of hemorrhoid medicines, and provides a hemorrhoid medicine, hemorrhoid steam-washing liquid and a preparation method thereof. The hemorrhoid medicine comprises the following raw materials in parts by weight: 50-200 parts of pilea clearwater, 500 parts of circium japonicum, 10-30 parts of white hyacinth bean, 10-50 parts of wormwood, 15-30 parts of motherwort and 25-150 parts of radix asparagi. The hemorrhoid steaming and washing liquid comprises hemorrhoid medicine, algefacient and antibacterial agent. The hemorrhoid medicine and hemorrhoid steaming and washing liquid have good efficacy and quick curative effect, and can quickly treat hemorrhoid. The preparation method of the hemorrhoid medicine can well retain the active ingredients of the medicinal materials and improve the medicinal effect of the medicinal materials. The preparation method of the hemorrhoid steaming and washing liquid is simple to operate, convenient to use, economical and practical.
Compositions, methods and kits for diagnosing and treating cancer and muscular disorders are provided. Therapeutic compositions may comprise agents that modulate sphingolipid metabolism and/or signaling pathways. Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous genes involved in sphingolipid metabolism. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided.
MPHOSPH 1-derived peptides and vaccines comprising the same are provided. The present invention provides MPHOSPH 1-derived epitope peptides having the ability to induce cytotoxic T cells. The invention also provides polynucleotides encoding the peptides, antigen presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, and methods of inducing antigen presenting cells or CTLs. The invention also provides compositions and pharmaceutical compositions containing them as active ingredients. In addition, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen presenting cells, cytotoxic T cells, or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
OXYGEN, COMPRESSED USP UN 1072 OXYGEN 2 (R-K14) 115856

WARNING: For emergency use only when administered by properly trained personnel for oxygen deficiency and resuscitation. For all other medical applications, Rx only. Uninterrupted use of high concentrations of oxygen over a long duration, without monitoring its effect on oxygen content of arterial blood, may be harmful. Do not attempt to use on patients who have stopped breathing unless used in conjunction with resuscitative equipment. Produced by Air Liquefaction.DANGER: MAY CAUSE OR INTENSIFY FIRE; OXIDIZER. CONTAINS GAS UNDER PRESSURE; MAY EXPLODE IF HEATED. Do not handle until all safety precautions have been read and understood. Keep and store away from clothing and other combustible materials. Keep valves and fittings free from grease and oil. Use and store only outdoors or in a well-ventilated place. In case of fire: Stop leak if safe to do so. Use a back flow preventive device in the piping. Use only with equipment of compatible materials of construction and rated for cylinder pressure. Use only with equipment cleaned for oxygen service. Open valve slowly. Close valve after each use and when empty. Protect from sunlight when ambient temperature exceeds 52°C (125° F). Read and follow the Safety Data Sheet (SDS) before use. CAS 7782-44-7 DO NOT REMOVE THIS PRODUCT LABEL.

Rev: 3/15
Techniques are provided for detection and treatment of tumors using ultrasound. An early detection test may be performed on a patient. A location of a tumor may be determined based on the early detection test. Properties of the tumor may be determined based on the early detection test. Moieties may be functionalized based on the properties of the tumor. The moieties maybe introduced into the patient. The location of the tumor may be imaged using ultrasound, magnetic resonance elastography, or computed tomography to generate images of the location of the tumor. A treatment plan based on the images of the location of the tumor may be implemented using ultrasound.
Colorectal cancer (CRC) is a highly prevalent malignancy affecting the digestive system on a global scale. This study aimed to explore the previously unexplored role of CHPF in the progression of CRC. Our results revealed a significant upregulation of CHPF expression in CRC tumour tissues compared to normal tissues, with its levels correlating with tumour malignancy. In vitro experiments using CRC cell lines demonstrated that inhibiting CHPF expression suppressed cell proliferation, colony formation and cell migration, while promoting apoptosis. Conversely, overexpressing CHPF had the opposite effect. Additionally, our xenograft models in mice confirmed the inhibitory impact of CHPF knockdown on CRC progression using various cell models. Mechanistic investigations unveiled that CHPF may enhance VEGFB expression through E2F1-mediated transcription. Functionally, suppressing VEGFB expression successfully mitigated the oncogenic effects induced by CHPF overexpression. Collectively, these findings suggest that CHPF may act as a tumour promoter in CRC, operating in a VEGFB-dependent manner and could be a potential target for therapeutic interventions in CRC treatment.
Current clinical therapeutic efficacy for the treatment of osteo- and rheumatoid-arthritis is obviously limited. Although mesenchymal stem cells (MSCs) are considered as a source of promising regenerative therapy, un-modified or genetically engineered MSCs injected in vivo restrict their clinical utility because of the low drug efficacy and unpredicted side effect, respectively. Herein, a strategy to enhance the migration efficacy of MSCs to inflamed joints via an inflammation-mediated education process is demonstrated. To reinforce the limited anti-inflammatory activity of MSCs, gold nanostar loaded with triamcinolone is conjugated to MSC. Furthermore, near-infrared laser-assisted photothermal therapy (PTT) induced by gold nanostar significantly elevates the anti-inflammatory efficacy of the developed drugs, even in advanced stage arthritis model. An immunological regulation mechanism study of PTT is first suggested in this study; the expression of the interleukin 22 receptor, implicated in the pathogenesis of arthritis, is downregulated in T lymphocytes by PTT, and Th17 differentiation from naïve CD4 T cell is inhibited. Collectively, inflammation-targeting MSCs conjugated with triamcinolone-loaded gold nanostar (Edu-MSCs-AuS-TA) promote the repolarization of macrophages and decrease neutrophil recruitment in joints. In addition, Edu-MSCs-AuS-TA significantly alleviate arthritis-associated pain, improve general locomotor activity, and more importantly, induce cartilage regeneration even for severe stages of arthritis model.
BACKGROUND: Bariatric surgery has been proven safe in end-stage kidney disease (ESKD); however, few studies have evaluated whether a history of bariatric surgery impacts transplant-specific outcomes. We hypothesize that a history of bariatric surgery at the time of transplant does not adversely impact transplant-specific outcomes.
METHODS: The IBM MarketScan Commercial Claims and Encounters database was queried for patients with a history of kidney transplant between 2000 and 2021. Patients were stratified into three groups based on bariatric surgery status and body mass index (BMI) at the time of transplant: patients with obesity (O), patients without obesity (NO), and patients with a history of bariatric surgery (BS). Inverse probability of treatment weighting was used to control for confounding. Adjusted hazard ratios (aHRs) describing the risk of transplant-specific and postoperative outcomes were estimated using weighted Kaplan-Meier curves. Primary outcomes included 30-day and 1-year risk of transplant-specific outcomes. Secondary outcomes included 30-day and 1-year postoperative complications and 30-day and 1-year risk of wound-related complications.
RESULTS: We identified 14,806 patients; 128 in the BS group, 1572 in the O group, and 13,106 in the NO group. There was no difference in 30-day or 1-year risk of transplant-specific complications between the BS and NO group or the O and NO group. Patients with obesity (O) were more likely to experience wound infection (aHR 1.49, 95% CI 1.12-1.99), wound dehiscence (aHR 2.2, 95% CI 1.5-3.2), and minor reoperation (aHR 1.52, 95% CI 1.23-1.89) at 1 year. BS patients had increased risk of wound infection at 1 year (aHR 2.79, 95% CI 1.26-6.16), but were without increase in risk of minor or major reoperation.
CONCLUSION: A history of bariatric surgery does not adversely affect transplant-specific outcomes after kidney transplant. Bariatric surgery can be safely utilized to improve the transplant candidacy of patients with obesity with CKD and ESKD.
Increased plasma concentrations of paroxetine occur in subjects with renal and hepatic impairment. The mean plasma concentrations in patients with creatinine clearance below 30 mL/min. were approximately 4 times greater than seen in normal volunteers. Patients with creatinine clearance of 30 to 60 mL/min. and patients with hepatic functional impairment had about a 2-fold increase in plasma concentrations (AUC, C ). max

The initial dosage should therefore be reduced in patients with severe renal or hepatic impairment, and upward titration, if necessary, should be at increased intervals (see ). DOSAGE AND ADMINISTRATION
The dose level for the first cohort in Part C will be decided following completion of Part A of the study for GSK3358699. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive GSK3358699, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter\^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
PURPOSE: Acetaminophen is the most common drug used to treat acute pain in the pediatric population, given its wide safety margin, low cost, and multiple routes for administration. We sought to determine the most efficacious route of acetaminophen administration for postoperative acute pain relief in the pediatric surgical population.
METHODS: We conducted a systematic review of randomized controlled trials (RCTs) that included children aged between 30 days and 17 yr who underwent any type of surgical procedure and that evaluated the analgesic efficacy of different routes of administration of acetaminophen for the treatment of postoperative pain. We searched MEDLINE, CENTRAL, Embase, CINAHL, LILACs, and Google Scholar databases for trials published from inception to 16 April 2023. We assessed the risk of bias in the included studies using the Cochrane Risk of Bias 1.0 tool. We performed a frequentist network meta-analysis using a random-effects model. Our primary outcome was postoperative pain using validated pain scales.
RESULTS: We screened 2,344 studies and included 14 trials with 829 participants in the analysis. We conducted a network meta-analysis for the period from zero to two hours, including six trials with 496 participants. There was no evidence of differences between intravenous vs rectal routes of administration of acetaminophen (difference in means, -0.28; 95% confidence interval [CI], -0.62 to 0.06; very low certainty of the evidence) and intravenous vs oral acetaminophen (difference in means, -0.60; 95% CI, -1.20 to 0.01; low certainty of the evidence). For the comparison of oral vs rectal routes, we found evidence favouring the oral route (difference in means, -0.88; 95% CI, -1.44 to -0.31; low certainty of the evidence). Few trials reported secondary outcomes of interest; when comparing the oral and rectal routes in the incidence of nausea and vomiting, there was no evidence of differences (relative risk, 1.20; 95% CI, 0.81 to 1.78).
CONCLUSION: The available evidence on the effect of the administration route of acetaminophen on postoperative pain in children is very uncertain. The outcomes of postoperative pain control and postoperative vomiting may differ very little between the oral and rectal route. Better designed and executed RCTs are required to address this important clinical question.
STUDY REGISTRATION: PROSPERO (CRD42021286495); first submitted 19 November 2021.